# Henry Skinner

> Henry Skinner is a Series A investor at AMR Action Fund backing Biotechnology. See 18 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [AMR Action Fund](https://shizune.co/investors/profile/amr-action-fund)
- Location: Boston, United States
- Total investments: 18
- Last investment: Jul 2026
- Lead investor: 56%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/henry-skinner/0/b78/aa2

Henry Skinner is a Series A investor at AMR Action Fund in Boston focused on Biotechnology and Health Care. Henry Skinner is Chief Executive Officer at AMR Action Fund. Attended Texas A&M University.

## Contacts

5 contacts available for Henry Skinner: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/dr-henry-skinner?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 16 | 89% |
| Health Care | 11 | 61% |
| Therapeutics | 9 | 50% |
| Medical | 7 | 39% |
| Pharmaceutical | 7 | 39% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 33% |
| Series B | 6 | 33% |
| Series C | 4 | 22% |
| Series E | 1 | 6% |
| Series H | 1 | 6% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 50% |
| United Kingdom | 3 | 17% |
| France | 2 | 11% |
| Spain | 1 | 6% |
| Iceland | 1 | 6% |

6 countries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Trellis Bioscience | Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact ofpotential therapeutic interventions. The company is based in San Francisco, California. | $9M | Series C | Jul 16, 2026 |  |
| Telum Therapeutics | Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages. | $20.5M | Series A | Jul 01, 2026 |  |
| Centauri Therapeutics | Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight theinfection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ strategy is to redirect naturally occurring antibodies to target disease. Centauri Therapeutics' unique Chemistry Platform provides a flexible scaffold to enable the synthesis of specific Alphamers. These are bifunctional molecules which present a selective cell binding moiety as well as an epitope that recruits pre-existing antibodies, resulting in cell killing. Centauri Therapeutics believes their technology is widely applicable in the treatment of life threatening infectious diseases. Companies with an interest in accessing Centauri’s Alphamer technology or with an interest in one of their current projects, are warmly encouraged to contact them to discuss partnering opportunities. In order to drive success in the important area of immuno-oncology, Centauri Therapeutics has established a joint venture, Avvinity Therapeutics, with Horizon Discovery in March 2016. Avvinity combines Centauri’s Alphamer Technology with the gene editing and oncology expertise of Horizon. In addition to Centauri Therapeutics' immuno-oncology joint venture, Centauri maintains a strong network of collaborators in the areas of aptamer selection, drug discovery, chemistry and immunology. | $8.1M | Series A | Feb 24, 2026 |  |
| Peptilogics | Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space but also ensuring that each potential therapeutic is biologically viable andscalable to manufacture. Peptilogics' lead clinical-stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need. | $78M | Series B | Oct 16, 2025 |  |
| TenNor Therapeutics | TenNor Therapeutics is a clinical stage, product development company with a sharp focus on unmet medical needs in the area of infectious diseases. The company possesses a dual-acting drug discovery platform with several innovative products in various stages of preclinical and clinical development. The company is developing new drugs for thetreatment of Helicobacter pylori infections, prosthetic joint infections, multidrug-resistant Gram-negative infections and some other common and serious infectious diseases. | $42.1M | Series E | Oct 16, 2024 |  |
| F2G | F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversifiedinto chemistry-driven discovery. They have also assembled an experienced development capacity. | $100M | Series H | Sep 12, 2024 |  |
| Elion Therapeutics | Elion Therapeutics is a cutting-edge biotechnology business focused on treating life-threatening IFIs. Elion was built on the notion that mechanistic insights allow for focused optimization of natural goods. | $81M | Series B | Jun 17, 2024 |  |
| Antabio | Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. Thecompany's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections.Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France. | $27M | Series B | Dec 12, 2023 |  |
| Venatorx Pharmaceuticals | Venatorx Pharmaceuticals is a private company that focuses on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The company was founded in 2010 and is headquartered in Malvern, Pennsylvania. | $34M | Series C | Apr 04, 2022 |  |
| Adaptive Phage Therapeutics | Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria. Its services are provided using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistantbacteria. | $20M | Series B | Apr 04, 2022 |  |

10 of 18 investments shown.

## Co-investors
- [Invivo Capital Partners](https://shizune.co/investors/profile/invivo-capital-partners) — VC Fund, 3 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 2 deals together
- [Earlybird Venture Capital](https://shizune.co/investors/profile/earlybird-venture-capital) — VC Fund, 2 deals together
- [Hyfinity Investments](https://shizune.co/investors/profile/hyfinity-investments) — VC Fund, 2 deals together
- [Nan Fung Life Sciences](https://shizune.co/investors/profile/nan-fung-life-sciences) — VC Fund, 2 deals together
- [Brunnur Ventures](https://shizune.co/investors/profile/venture-capital-fund-brunnur) — VC Fund, 2 deals together

## About AMR Action Fund

VC Fund · Boston, United States

AMR Action Fund renders investment, healthcare, biotech, research and development, pharmaceutical, and antibiotic services. They invest in firms that are developing critical pathogen therapies and lobby for market reforms to transform how society values these lifesaving drugs. They aim to help launch two to four new antimicrobials over the nextdecade and build a sustainable investment environment.

2 contacts available at AMR Action Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Henry Skinner | Chief Executive Officer | — |
| Sergei Petukhov | Managing Director | — |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Henry Skinner invest in?

Henry Skinner invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Henry Skinner?

Public channels for Henry Skinner include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Henry Skinner last invest?

The most recent investment recorded for Henry Skinner closed in Jul 2026. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co